2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension

Journal of Hypertension, Год журнала: 2023, Номер 41(12), С. 1874 - 2071

Опубликована: Июнь 24, 2023

Document Reviewers: Luis Alcocer (Mexico), Christina Antza (Greece), Mustafa Arici (Turkey), Eduardo Barbosa (Brazil), Adel Berbari (Lebanon), Luís Bronze (Portugal), John Chalmers (Australia), Tine De Backer (Belgium), Alejandro de la Sierra (Spain), Kyriakos Dimitriadis Dorota Drozdz (Poland), Béatrice Duly-Bouhanick (France), Brent M. Egan (USA), Serap Erdine Claudio Ferri (Italy), Slavomira Filipova (Slovak Republic), Anthony Heagerty (UK), Michael Hecht Olsen (Denmark), Dagmara Hering Sang Hyun Ihm (South Korea), Uday Jadhav (India), Manolis Kallistratos Kazuomi Kario (Japan), Vasilios Kotsis Adi Leiba (Israel), Patricio López-Jaramillo (Colombia), Hans-Peter Marti (Norway), Terry McCormack Paolo Mulatero Dike B. Ojji (Nigeria), Sungha Park Priit Pauklin (Estonia), Sabine Perl (Austria), Arman Postadzhian (Bulgaria), Aleksander Prejbisz Venkata Ram Ramiro Sanchez (Argentina), Markus Schlaich Alta Schutte Cristina Sekib Sokolovic (Bosnia and Herzegovina), Jonas Spaak (Sweden), Dimitrios Terentes-Printzios Bruno Trimarco Thomas Unger (The Netherlands), Bert-Jan van den Born Anna Vachulova Agostino Virdis Jiguang Wang (China), Ulrich Wenzel (Germany), Paul Whelton Jiri Widimsky (Czech Jacek Wolf Grégoire Wuerzner (Switzerland), Eugene Yang Yuqing Zhang (China).

Язык: Английский

---

Dynamics of platelet hemostasis indicators in different blood pressure profiles in elderly and middle-aged hypertensive patients under combined antihypertensive treatment

Ageing & Longevity, Год журнала: 2025, Номер 1.2025, С. 22 - 27

Опубликована: Янв. 18, 2025

In addition to achieving target blood pressure levels an equally important task is risk stratification of probable thrombotic complications in arterial hypertension the elderly. This reflected updated recommendations for implementing elderly patients with hypertension. Studies platelet activation provide implementation basis new approaches pharmacological prevention associated increased thrombus formation. Antihypertensive drugs have different effects on hemostasis parameters, which requires further study. Thus, this article attempts systematise and analyse some literature data standard antihypertensive effect. The purpose was conduct a comparative assessment parameters dynamics middle-aged hypertensive depending daily rhythm under combined treatment enalapril amlodipine. work based special examination 93 127 who were inpatient two-week treatment. state spontaneous induced aggregation determined. When analysing significant prolongation time maximal from 3.3 ± 0.9 min 9.3 0.4 amlodipine noteworthy (p<0.05). Analysing indicators dipper group we established decrease (p <0.05) amplitude by 32% 28%. analysis platelets showed that non-dipper group, slowed down according slope 66.7% ADP-inducer 37.6% With insufficient nocturnal reduction during ADP-initiated significantly decreased 29.9% <0.05). There acceleration 63.6% adrenaline-stimulated aggregation. It can be concluded effect depends initial profile. all confirms thrombogenic potential Among profile, should considered due their involvement high-risk events. Keywords: hypertension; essential aggregation;

Язык: Английский

---

Single-pill combination for treatment of hypertension: Just a matter of practicality or is there a real clinical benefit?

European Journal of Internal Medicine, Год журнала: 2024, Номер 126, С. 16 - 25

Опубликована: Апрель 23, 2024

Язык: Английский

---

The Polypill: A New Alternative in the Prevention and Treatment of Cardiovascular Disease

Journal of Clinical Medicine, Год журнала: 2024, Номер 13(11), С. 3179 - 3179

Опубликована: Май 29, 2024

Cardiovascular disease (CVD) is the primary cause of death and disability worldwide. Although age-standardized CVD mortality rates decreased globally by 14.5% between 2006 2016, burden remains disproportionately higher in low- middle-income countries compared to high-income countries. Even though proven, effective approaches based on multiple-drug intake aimed at prevention treatment are currently available, poor adherence, early discontinuation treatment, suboptimal daily execution prescribed therapeutic regimes give rise shortfalls drug exposure, leading high variability responses medications. Wald Law, their landmark paper published BMJ 2003, hypothesized that use a fixed-dose combination statins, β-blockers, angiotensin receptor blockers, angiotensin-converting enzyme inhibitors, aspirin (classic Polypill composition) may increase adherence decrease up 80% when as or substitution traditional protocols. Since then, many clinical trials have tested this hypothesis, with comparable results. This review aims describe available performed assess impact combinations cost-effectiveness, risk factors critical onset CVD.

Язык: Английский

---

Adherence to perindopril/amlodipine/atorvastatin combination according to the administration strategy

European Heart Journal - Quality of Care and Clinical Outcomes, Год журнала: 2025, Номер unknown

Опубликована: Янв. 6, 2025

Abstract Aims To compare adherence to perindopril/amlodipine/atorvastatin combination administrated as a polypill (one pill) vs. separate tablets. Methods and results Using the healthcare utilization database of Lombardy (Italy), 1110 patients who received during 2019–2021 were matched with prescribed same in tablets or two antihypertensive drugs single tablet lipid-lowering drug separately. Adherence treatment was assessed over year after first dispensation proportion follow-up days covered by prescription (PDC). Patients PDC &gt;75% &lt;25% defined highly poorly adherent, respectively. dynamics time evaluated through group-based trajectory modelling. Cardiovascular-related costs also assessed. Log-binomial regression models fitted estimate risk ratio (RR) associated administration strategy. Among separate-pill users, 60% 18% showed high adherence, respectively; corresponding figures for low 5% 37%. Compared combination, increased propensity be adherent 3.29 times (95% confidence interval: 2.88–3.75) reduced (RR = 0.13, 0.10–0.18), irrespective sex, age, comorbidities, co-treatment burden throughout entire follow-up. The lower (€676 €1068, P 0.003). Conclusion In real-life setting, improved compared combination. These findings support current guidelines favour polypill.

Язык: Английский

---

ERC-funded Advanced Grant: creating molecular polypills

European Heart Journal, Год журнала: 2025, Номер unknown

Опубликована: Фев. 6, 2025

Journal Article ERC-funded Advanced Grant: creating molecular polypills Get access Georgios Krilis, Krilis Centre for Cardiovascular Sciences, The Queen's Medical Research Institute, University of Edinburgh, 47 Little France Crescent, Edinburgh EH16 4TJ, UK https://orcid.org/0000-0001-5988-9244 Search other works by this author on: Oxford Academic PubMed Google Scholar Abdelaziz Beqqali, Beqqali https://orcid.org/0000-0003-1390-5821 Andrew H Baker UKDepartment Pathology, CARIM School Diseases, Maastricht University, Universiteitssingel 50, 6229 ER Maastricht, Netherlands Corresponding author. Email: [email protected] https://orcid.org/0000-0003-1441-5576 European Heart Journal, ehae866, https://doi.org/10.1093/eurheartj/ehae866 Published: 06 February 2025

Язык: Английский

---

Blue Mussel-Derived Bioactive Peptides PIISVYWK (P1) and FSVVPSPK (P2): Promising Agents for Inhibiting Foam Cell Formation and Inflammation in Cardiovascular Diseases

Marine Drugs, Год журнала: 2024, Номер 22(10), С. 466 - 466

Опубликована: Окт. 10, 2024

Atherosclerosis is a key etiological event in the development of cardiovascular diseases (CVDs), strongly linked to formation foam cells. This study explored effects two blue mussel-derived bioactive peptides (BAPs), PIISVYWK (P1) and FSVVPSPK (P2), on inhibiting cell mitigating inflammation oxLDL-treated RAW264.7 macrophages. Both significantly suppressed intracellular lipid accumulation cholesterol levels while promoting efflux by downregulating cluster differentiation 36 (CD36) class A1 scavenger receptors (SR-A1) upregulating ATP binding cassette subfamily A member 1 (ABCA-1) G (ABCG-1) expressions. The increased expression peroxisome proliferator-activated receptor-gamma (PPAR-γ) liver X receptor-alpha (LXR-α) further validated their role enhancing efflux. Additionally, P1 P2 inhibited human aortic smooth muscle cells exerted anti-inflammatory reducing pro-inflammatory cytokines, nitric oxide (NO), prostaglandin E

Язык: Английский

---

Redefining the polypill: pros and cons in cardiovascular precision medicine

Frontiers in Pharmacology, Год журнала: 2023, Номер 14

Опубликована: Сен. 19, 2023

Polypill is a multi-drug formulation in single pill intended to simplify the drug regimen and reduce medication-induced adverse effects. The most common multidrug combinations polypill are used treat cardiovascular diseases targeted against key modifiable risk factors such as hypertension hyperlipidemia. These contain blood-pressure lowering agents, statins, anti-platelet agents usually fixed dose. Polypills can be an affordable therapeutic intervention for treating high-risk patients, these proven increase patients' adherence medication improve clinical outcomes. Over previous years, randomized trials of several polypills have yielded contradictory findings, raising skepticism regarding their widespread use primary disease prevention. Here, we reviewed concept polypills, evidence-based strengths, limitations this polypharmacy strategy, discussed future directions secondary preventive management associated factors.

Язык: Английский

---

The CNIC-polypill (acetylsalicylic acid, atorvastatin, and ramipril), an effective and cost-saving secondary prevention strategy compared with other therapeutic options in patients with ischaemic heart disease

European Heart Journal Open, Год журнала: 2024, Номер 4(2)

Опубликована: Март 1, 2024

The retrospective NEPTUNO study evaluated the effectiveness of Centro Nacional de Investigaciones Cardiovasculares (CNIC)-polypill (including acetylsalicylic acid, ramipril, and atorvastatin) vs. other therapeutic approaches in secondary prevention for cardiovascular (CV) disease. In this substudy, focus was on subgroup patients with ischaemic heart disease (IHD).

Язык: Английский

---

Evolving Concepts of the SCORE System: Subtracting Cholesterol from Risk Estimation: A Way for a Healthy Longevity?

Life, Год журнала: 2024, Номер 14(6), С. 679 - 679

Опубликована: Май 24, 2024

The role of cholesterol, mainly low-density lipoproteins (LDL-C), as a causal risk factor for atherosclerotic cardiovascular disease (ASCVD) is now established and accepted by the international scientific community. Based on this evidence, European American guidelines recommend early stratification "rapid" achievement suggested target according to estimation reduce number major events. Prolonged exposure over years high levels LDL-C one determining factors in development progression plaque, which action conventional (cigarette smoking, excess weight, sedentary lifestyle, arterial hypertension, diabetes mellitus) well non-conventional (gut microbiota, hyperuricemia, inflammation), alone or combination, favors destabilization lesion with rupture/fissuration/ulceration consequent formation intravascular thrombosis, leads acute clinical manifestations coronary syndromes. In current practice, there growing cases that, although extremely common, are emblematic concept long-term (LDL hypercholesterolemia), which, not adequately controlled combination other factors, has favored onset triple "go lower, start earlier keep longer!" should be applied practice at any level prevention. present manuscript, we will review evidence documents supporting ASCVD whether it time remove from score.

Язык: Английский

---